Published in J Nucl Med on May 01, 2006
Exclusion of malignancy in thyroid nodules with indeterminate fine-needle aspiration cytology after negative 18F-fluorodeoxyglucose positron emission tomography: interim analysis. World J Surg (2010) 1.57
Evaluation of a thyroid nodule. Otolaryngol Clin North Am (2010) 1.01
Thyroid nodules. Med Clin North Am (2012) 0.94
The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Prognostication, Diagnosis, and Management of Thyroid Carcinoma. J Thyroid Res (2011) 0.90
Imaging for staging and management of thyroid cancer. Cancer Imaging (2008) 0.89
Imaging of the thyroid: Recent advances. Indian J Endocrinol Metab (2012) 0.85
The role of 18F-fluorodeoxyglucose positron emission tomography in thyroid neoplasms. Oncologist (2011) 0.85
Is fluorine-18 fluorodeoxyglucose positron emission tomography useful for the thyroid nodules with indeterminate fine needle aspiration biopsy? A meta-analysis of the literature. J Otolaryngol Head Neck Surg (2013) 0.84
A Case Report: The Diagnosis and Therapeutic Evaluation for a Rare Disease of Langerhans Cell Histiocytosis Involving Thyroid. Medicine (Baltimore) (2015) 0.82
The usefulness of standardized uptake value in differentiation between benign and malignant thyroid lesions detected incidentally in 18F-FDG PET/CT examination. PLoS One (2014) 0.80
Could 18F-FDG-PET/CT avoid unnecessary thyroidectomies in patients with cytological diagnosis of follicular neoplasm? Langenbecks Arch Surg (2013) 0.80
18F-FDG PET of thyroid nodules with inconclusive cytologic results. J Nucl Med (2006) 0.76
A prospective cohort study to assess the role of FDG-PET in differentiating benign and malignant follicular neoplasms. Ann Med Surg (Lond) (2016) 0.75
Current role of radionuclide imaging in differentiated thyroid cancer. Cancer Imaging (2008) 0.75
Role of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Evaluation of Cytologically Indeterminate Thyroid Nodules. Iran J Radiol (2016) 0.75
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
New common variants affecting susceptibility to basal cell carcinoma. Nat Genet (2009) 4.15
The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging (2008) 3.24
Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol (2009) 2.84
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg (2006) 2.62
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32
Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Ann Neurol (2011) 2.30
The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging (2013) 2.25
Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 2.23
The value of 18F-FDG PET/CT in diagnosing infectious endocarditis. Eur J Nucl Med Mol Imaging (2013) 2.13
Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst Rev (2012) 2.11
Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol (2013) 2.04
Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET. Radiology (2005) 2.02
Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin. Diabetologia (2014) 2.00
A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore) (2007) 1.87
PET/CT: panacea, redundancy, or something in between? J Nucl Med (2004) 1.86
Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol (2010) 1.86
Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med (2009) 1.80
Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med (2010) 1.71
18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med (2013) 1.69
Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging (2006) 1.66
Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis. J Nucl Med (2006) 1.61
99mTc-labeled interleukin 8 for the scintigraphic detection of infection and inflammation: first clinical evaluation. J Nucl Med (2007) 1.61
Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. J Nucl Med (2005) 1.57
Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med (2003) 1.56
Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm (2002) 1.55
F-18-fluorodeoxyglucose positron emission tomography combined with CT in critically ill patients with suspected infection. Intensive Care Med (2009) 1.55
PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncol (2010) 1.55
Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med (2009) 1.54
Increased metabolic activity of indolent liver metastases after resection of a primary colorectal tumor. J Nucl Med (2008) 1.50
Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer (2007) 1.50
Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. Eur J Nucl Med Mol Imaging (2013) 1.49
68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging (2010) 1.48
A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med (2010) 1.47
Combination of biomarkers for the discrimination between bacterial and viral lower respiratory tract infections. J Infect (2012) 1.47
Scintigraphic imaging of infectious foci with an 111In-LTB4 antagonist is based on in vivo labeling of granulocytes. J Nucl Med (2005) 1.47
Prognostic importance of the extent of ulceration in patients with clinically localized cutaneous melanoma. Ann Surg (2012) 1.46
Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med (2010) 1.46
Bone SPECT reduces the number of unnecessary mandibular resections in patients with squamous cell carcinoma. Oral Oncol (2005) 1.44
[Persistent fatigue following Q fever]. Ned Tijdschr Geneeskd (2012) 1.43
99mTc-HMPAO-labeled autologous versus heterologous leukocytes for imaging infection. J Nucl Med (2002) 1.41
Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer (2006) 1.38
Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. J Nucl Med (2006) 1.37
Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res (2013) 1.35
Diagnosis of renal and hepatic cyst infections by 18-F-fluorodeoxyglucose positron emission tomography in autosomal dominant polycystic kidney disease. Am J Kidney Dis (2003) 1.34
Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med (2006) 1.34
The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol (2009) 1.33
Comparison of image-derived and arterial input functions for estimating the rate of glucose metabolism in therapy-monitoring 18F-FDG PET studies. J Nucl Med (2006) 1.32
Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med (2007) 1.31
Image-quality assessment for several positron emitters using the NEMA NU 4-2008 standards in the Siemens Inveon small-animal PET scanner. J Nucl Med (2010) 1.30
Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur J Nucl Med Mol Imaging (2003) 1.30
The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer (2005) 1.29
Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res (2011) 1.29
A novel iterative method for lesion delineation and volumetric quantification with FDG PET. Nucl Med Commun (2007) 1.27
18F-FDG PET/CT for detection of metastatic infection in gram-positive bacteremia. J Nucl Med (2010) 1.27
Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging (2010) 1.26
Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med (2009) 1.26
2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study. J Clin Oncol (2005) 1.26
Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation (2004) 1.26
Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res (2009) 1.24
Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes. Org Biomol Chem (2007) 1.24
A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. Eur J Nucl Med Mol Imaging (2006) 1.24
18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy. J Nucl Med (2013) 1.21
PET and SPECT in osteomyelitis and prosthetic bone and joint infections: a systematic review. Semin Nucl Med (2010) 1.21
18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med (2007) 1.20
Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging. Proc Natl Acad Sci U S A (2011) 1.19
Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. Nucl Med Biol (2007) 1.18
Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: a prospective multicenter trial. Radiother Oncol (2008) 1.17
Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation. Lung Cancer (2011) 1.15
ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med (2010) 1.14
Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther (2010) 1.13